Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G5CF
|
|||
| Former ID |
DCL000782
|
|||
| Drug Name |
Doxercalciferol
|
|||
| Synonyms |
Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic kidney disease [ICD-11: GB61; ICD-10: N18, N18.9] | Approved | [1], [2] | |
| Company |
Genzyme
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H44O2
|
|||
| Canonical SMILES |
CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
|
|||
| InChI |
1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
|
|||
| InChIKey |
HKXBNHCUPKIYDM-CGMHZMFXSA-N
|
|||
| CAS Number |
CAS 54573-75-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10410, 7848072, 8616516, 11528742, 14714977, 14757783, 14831187, 26759741, 39290018, 47721666, 50096685, 50140476, 53790000, 57358018, 71855033, 103770793, 109693717, 113854564, 126670553, 127324039, 127324040, 127324041, 134957119, 135079074, 135651481, 135698305, 137248797, 142560574, 143493351, 144206531, 152164533, 152238015, 152258777, 160647628, 162189015, 163687121, 164227093, 165238070, 175266149, 176264149, 184593516, 184812060, 210277996, 223439572, 223860398, 226660079, 251915651, 251917001, 252157093, 252160414
|
|||
| ChEBI ID |
CHEBI:4712
|
|||
| ADReCS Drug ID | BADD_D00722 | |||
| SuperDrug ATC ID |
H05BX03
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vitamin D3 receptor (VDR) | Target Info | Antagonist | [2] |
| KEGG Pathway | Endocrine and other factor-regulated calcium reabsorption | |||
| Mineral absorption | ||||
| Tuberculosis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Vitamin D metabolism and pathway | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Direct p53 effectors | ||||
| RXR and RAR heterodimerization with other nuclear receptor | ||||
| Retinoic acid receptors-mediated signaling | ||||
| Validated transcriptional targets of deltaNp63 isoforms | ||||
| Validated transcriptional targets of TAp63 isoforms | ||||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Ovarian Infertility Genes | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Vitamin D Receptor Pathway | ||||
| Drug Induction of Bile Acid Pathway | ||||
| Nuclear Receptors | ||||
| Vitamin D Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2790). | |||
| REF 2 | Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.